News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.


Research More. Spend Less.

Spend $650 or more and get 20% off*

(*Offer valid in the US only. Expires June 30, 2017)


To Purchase # 4401S

4401S 2.5 mg $69.00.0


Find answers on our FAQs page.


PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools


Western blot analysis of extracts from KARPAS-299 cells, untreated or treated with crizotinib (1 hr) at the indicated concentrations, using Phospho-ALK (Tyr1604) Antibody #3341 (upper) or ALK (D5F3) XP® Rabbit mAb #3633 (lower).

Learn more about how we get our images

Chemical structure of crizotinib.

Learn more about how we get our images

Product Usage Information

Crizotinib is supplied as a lyophilized powder. For a 1 mM stock, reconstitute the 2.5 mg in 5.55 ml DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 0.1-1 µM for 2-6 h. Soluble in DMSO at 25 mg/ml with warming; very poorly soluble in water with maximum solubility ~10-20 µM.

Storage: Store lyophilized or in solution at -20ºC, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Product Description

Molecular Weight:

450.34 g/mol



Molecular Formula:


Crizotinib, also known as PF-02341066, is a novel, ATP-competitive receptor kinase inhibitor, showing high specificity for c-Met and anaplastic lymphoma kinase (ALK) over 120 other diverse kinases (1,2). Researchers have shown that crizotinib inhibits c-Met phosphorylation and c-Met-dependent proliferation, migration, and invasion of human tumor cells in vitro (IC50 values of 5–20 nM) (1). Crizotinib is effective against the constitutively active oncogenic fusion protein nucleophosmin (NPM)-ALK, inhibiting its phosphorylation (mean IC50 of 24 nM), inhibiting cell growth, and inducing G1-S phase cell cycle arrest and apoptosis in the ALK-positive ALCL (anaplastic large-cell lymphoma) cell lines KARPAS-299 and SU-DHL-1 (2).

1.  Zou, H.Y. et al. (2007) Cancer Res 67, 4408-17.

2.  Christensen, J.G. et al. (2007) Mol Cancer Ther 6, 3314-22.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.